In the Real World: Infections Associated with Biologic and Small Molecule Therapies in Psoriatic Arthritis and Psoriasis

Sarah A.R. Siegel, Kevin Winthrop

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Purpose of Review: To summarize our most current understanding of the real world risk of infections associated with biologic and small molecule therapies in the setting of psoriatic disease. Recent Findings: Patients with psoriasis or psoriatic arthritis are at increased risk for infection from both their disease and some of their therapies. There is little real world data for biologic and small molecule therapies; however, ustekinumab and biologics inhibiting IL-17 or IL-23 appear to have reduced risk estimates compared to anti-TNF therapies. Apremilast seems to have little infectious signal with limited real world data, and for JAK inhibitors, limited real world data suggest a higher risk of herpes zoster. Summary: Recently approved targeted and small molecule therapies for psoriasis carry infectious risks for patients, although they appear to vary across mechanism of action. As these treatments become more widespread, and additional therapies are approved, it will be imperative to evaluate their safety in the context of real world data.

Original languageEnglish (US)
Article number36
JournalCurrent rheumatology reports
Volume21
Issue number7
DOIs
StatePublished - Jul 1 2019

Fingerprint

Psoriatic Arthritis
Psoriasis
Infection
Therapeutics
Interleukin-23
Interleukin-17
Herpes Zoster
Biological Products
Safety

Keywords

  • Biologics
  • Opportunistic infection
  • PsA
  • PsO
  • Serious infections

ASJC Scopus subject areas

  • Rheumatology

Cite this

In the Real World : Infections Associated with Biologic and Small Molecule Therapies in Psoriatic Arthritis and Psoriasis. / Siegel, Sarah A.R.; Winthrop, Kevin.

In: Current rheumatology reports, Vol. 21, No. 7, 36, 01.07.2019.

Research output: Contribution to journalReview article

@article{b9cf2dfc309b4f2bb9ed0a223aeba666,
title = "In the Real World: Infections Associated with Biologic and Small Molecule Therapies in Psoriatic Arthritis and Psoriasis",
abstract = "Purpose of Review: To summarize our most current understanding of the real world risk of infections associated with biologic and small molecule therapies in the setting of psoriatic disease. Recent Findings: Patients with psoriasis or psoriatic arthritis are at increased risk for infection from both their disease and some of their therapies. There is little real world data for biologic and small molecule therapies; however, ustekinumab and biologics inhibiting IL-17 or IL-23 appear to have reduced risk estimates compared to anti-TNF therapies. Apremilast seems to have little infectious signal with limited real world data, and for JAK inhibitors, limited real world data suggest a higher risk of herpes zoster. Summary: Recently approved targeted and small molecule therapies for psoriasis carry infectious risks for patients, although they appear to vary across mechanism of action. As these treatments become more widespread, and additional therapies are approved, it will be imperative to evaluate their safety in the context of real world data.",
keywords = "Biologics, Opportunistic infection, PsA, PsO, Serious infections",
author = "Siegel, {Sarah A.R.} and Kevin Winthrop",
year = "2019",
month = "7",
day = "1",
doi = "10.1007/s11926-019-0832-y",
language = "English (US)",
volume = "21",
journal = "Current Rheumatology Reports",
issn = "1523-3774",
publisher = "Current Science, Inc.",
number = "7",

}

TY - JOUR

T1 - In the Real World

T2 - Infections Associated with Biologic and Small Molecule Therapies in Psoriatic Arthritis and Psoriasis

AU - Siegel, Sarah A.R.

AU - Winthrop, Kevin

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Purpose of Review: To summarize our most current understanding of the real world risk of infections associated with biologic and small molecule therapies in the setting of psoriatic disease. Recent Findings: Patients with psoriasis or psoriatic arthritis are at increased risk for infection from both their disease and some of their therapies. There is little real world data for biologic and small molecule therapies; however, ustekinumab and biologics inhibiting IL-17 or IL-23 appear to have reduced risk estimates compared to anti-TNF therapies. Apremilast seems to have little infectious signal with limited real world data, and for JAK inhibitors, limited real world data suggest a higher risk of herpes zoster. Summary: Recently approved targeted and small molecule therapies for psoriasis carry infectious risks for patients, although they appear to vary across mechanism of action. As these treatments become more widespread, and additional therapies are approved, it will be imperative to evaluate their safety in the context of real world data.

AB - Purpose of Review: To summarize our most current understanding of the real world risk of infections associated with biologic and small molecule therapies in the setting of psoriatic disease. Recent Findings: Patients with psoriasis or psoriatic arthritis are at increased risk for infection from both their disease and some of their therapies. There is little real world data for biologic and small molecule therapies; however, ustekinumab and biologics inhibiting IL-17 or IL-23 appear to have reduced risk estimates compared to anti-TNF therapies. Apremilast seems to have little infectious signal with limited real world data, and for JAK inhibitors, limited real world data suggest a higher risk of herpes zoster. Summary: Recently approved targeted and small molecule therapies for psoriasis carry infectious risks for patients, although they appear to vary across mechanism of action. As these treatments become more widespread, and additional therapies are approved, it will be imperative to evaluate their safety in the context of real world data.

KW - Biologics

KW - Opportunistic infection

KW - PsA

KW - PsO

KW - Serious infections

UR - http://www.scopus.com/inward/record.url?scp=85066956411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066956411&partnerID=8YFLogxK

U2 - 10.1007/s11926-019-0832-y

DO - 10.1007/s11926-019-0832-y

M3 - Review article

C2 - 31172303

AN - SCOPUS:85066956411

VL - 21

JO - Current Rheumatology Reports

JF - Current Rheumatology Reports

SN - 1523-3774

IS - 7

M1 - 36

ER -